Search





Search





Markets
/
Stocks
/
nasdaq-mrna
/

Moderna Inc

MRNA

Add to Watchlist

61.000USD

+1.655+2.79%

Close 06/23, 16:00（ET）Quotes delayed by 15 min

23.85BMarket Cap

LossP/E TTM

Moderna Inc

61.000

+1.655+2.79%

Overview

Financials

Discussions

Analysis

Company

View Detailed Chart

TradingKey 图表

Intraday

30m

Today

+2.79%

5 Days

+10.11%

1 Month

+30.12%

6 Months

+88.91%

Year to Date

+106.85%

1 Year

+137.63%

Key Figures

59.050Open

63.980High

6.81MVolume

LossP/E TTM

LossP/E Dynamic

--Dividend TTM

1.74%Turnover Ratio

59.345Prev. Close

58.340Low

310.73MTurnover

LossP/E Static

2.56P/B

0.00%Div Yield TTM

-26.41%ROA

59.55052wk High

0.53Volume Ratio

-3.56BNet Profit

391.00MShares

-8.1390EPS TTM

1.06Beta

-36.56%ROE

22.28052wk Low

9.50%Amplitude

-135.73%Gross Margin

23.85BMarket Cap

7.08Reward/Risk

3.75%Risk Rate

TradingKey Stock Score of Moderna Inc

Currency: USD Updated: 2026-06-22

Key Insights

Moderna Inc's fundamentals are relatively healthy, and its growth potential is significant.Its valuation is considered fairly valued, ranking 75 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 48.16.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Moderna Inc's Score

Industry at a Glance

Industry Ranking

75 / 157

Overall Ranking

186 / 4577

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

43°C



Very Low

Very High

Neutral

Moderna Inc Highlights

StrengthsRisks

Moderna, Inc. is a biotechnology company. The Company is advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a spectrum of diseases. The Company’s diverse development pipeline consists of 44 therapeutic and vaccine programs, 11 of which are in late-stage development. Its commercial products include Spikevax (its COVID vaccine) and mRESVIA (its respiratory syncytial virus (RSV) vaccine). Additionally, it has achieved four positive Phase III data readouts for its COVID vaccine (mRNA-1283), its RSV vaccine for high-risk adults aged 18 to 59 (mRNA-1345), its seasonal flu+COVID vaccine (mRNA-1083), and its seasonal flu vaccine (mRNA-1010).

Fairly Valued

The company’s latest PE is -7.29, at a medium 3-year percentile range.

Institutional Buying

The latest institutional holdings are 313.06M shares, increasing 3.13% quarter-over-quarter.

Held by Paul Tudor Jones

Star Investor Paul Tudor Jones holds 152.70K shares of this stock.

Analyst Rating

Based on 25 analysts

Hold

Current Rating

48.312

Target Price

-18.59%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Moderna Inc News

Hantavirus Appears Sporadically, Is Now the Opportunity to Buy Vaccine Concept Stock Moderna?

TradingKey - As of May 7, the World Health Organization (WHO) has confirmed eight cases of hantavirus infection associated with the cruise ship, including three deaths. The Andes strain of the virus is the only hantavirus subtype known to be capable of limited person-to-person transmission.

TradingKeySun, May 10

Should You Listen to Billionaires to Buy Moderna Stock in 2026?

A useful rule of thumb is to think of billionaire interest as a prompt to re-underwrite the story. Question: Can Moderna’s respiratory franchise stabilize and grow with flu, can the oncology pipeline provide a 2nd growth leg in a few years, and is the current valuation adequately discounting clinica

TradingKeyTue, Mar 3